Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Washington University School of Medicine
Yale University
Baptist Health South Florida
Maastricht University Medical Center
Tianjin Medical University Cancer Institute and Hospital
Vanderbilt-Ingram Cancer Center
The Cooper Health System
Exelixis
Duke University
King's College Hospital NHS Trust
Insel Gruppe AG, University Hospital Bern
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
The Methodist Hospital Research Institute
Hospital del Rio Hortega
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
Zhejiang Cancer Hospital
Medical College of Wisconsin
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Medical College of Wisconsin
University of Cincinnati
Beta Emitting Accurate Monitored Systems
Nationwide Children's Hospital
Medical College of Wisconsin
Sun Yat-sen University
Peking University Cancer Hospital & Institute
University Hospital, Toulouse
Centre Paul Strauss
Case Comprehensive Cancer Center
University of Vermont Medical Center
First Affiliated Hospital, Sun Yat-Sen University
University College, London
University of South Florida
Kaohsiung Medical University Chung-Ho Memorial Hospital
University Hospital, Angers
University of Health Sciences Lahore
University of Virginia
Hamilton Health Sciences Corporation
Imperial College London
Bagcilar Training and Research Hospital
Copernicus Memorial Hospital
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Institut de cancérologie Strasbourg Europe
Guangzhou Medical University
University of Health Sciences Lahore
Convalife (Shanghai) Co., Ltd.